经口腔吸入及鼻腔给药人体药物代谢动力学研究实施体会_West China Medical Journal

Authors：

 罗柱 , 王颖

Corresponding author：

Keywords：

口腔; 鼻腔; 给药; 药物代谢动力学

DOI：

10.7507/1002-0179.20140286

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

经口腔吸入及鼻腔给药的药物制剂日趋增多，通常具有血药浓度低，容易发生沾染，药物吸收入血迅速等特点，根据口、鼻腔给药的特点及影响因素，确保给药剂量的标准化，防止药物沾染是实现此类方式给药的重要问题。结合工作实践，现就经口、鼻腔给药制剂人体药物代谢动力学研究过程中的注意事项予以讨论交流，以供参考。

Citation： 罗柱, 王颖. 经口腔吸入及鼻腔给药人体药物代谢动力学研究实施体会. West China Medical Journal, 2014, 29(5): 940-941. doi: 10.7507/1002-0179.20140286 Copy

1.	Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2011)[R/OL]. Bethesda:Global Initiative for Asthma. (2012-05-05)[2013-09-20]. http://www.ginasthma.org/local/uploads/files/GINA_Report2011_May4.pdf.
2.	Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease (revised 2011)[R/OL]. Vancouver:Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2012-02-21)[2013-09-20]. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf.
3.	Illum L. Nasal drug delivery-recent developments and future prospects[J]. J Control Release, 2012, 161(2):254-263.
4.	Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics[J]. J Drug Target, 2012, 20(6):481-501.
5.	Campbell C, Morimoto BH, Nenciu D, et al. Drug development of intranasally delivered peptides[J]. Ther Deliv, 2012, 3(4):557-568.
6.	Illum L. Nasal drug delivery:new developments and strategies[J]. Drug Discov Today, 2002, 7(23):1184-1189.
7.	Romeo VD, deMeireles J, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery[J]. Adv Drug Deliv Rev, 1998, 29(1-2):89-116.
8.	Merkus FW, Verhoef JC, Schipper NG, et al. Nasal mucociliary clearance as a factor in nasal drug delivery[J]. Adv Drug Del Rev, 1998, 29(1-2):13-38.
9.	蒋新国. 药物的鼻腔黏膜吸收[J]. 中国新药杂志, 2003, 12(11):902-905.

1. Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2011)[R/OL]. Bethesda:Global Initiative for Asthma. (2012-05-05)[2013-09-20]. http://www.ginasthma.org/local/uploads/files/GINA_Report2011_May4.pdf.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease (revised 2011)[R/OL]. Vancouver:Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2012-02-21)[2013-09-20]. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf.
3. Illum L. Nasal drug delivery-recent developments and future prospects[J]. J Control Release, 2012, 161(2):254-263.
4. Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics[J]. J Drug Target, 2012, 20(6):481-501.
5. Campbell C, Morimoto BH, Nenciu D, et al. Drug development of intranasally delivered peptides[J]. Ther Deliv, 2012, 3(4):557-568.
6. Illum L. Nasal drug delivery:new developments and strategies[J]. Drug Discov Today, 2002, 7(23):1184-1189.
7. Romeo VD, deMeireles J, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery[J]. Adv Drug Deliv Rev, 1998, 29(1-2):89-116.
8. Merkus FW, Verhoef JC, Schipper NG, et al. Nasal mucociliary clearance as a factor in nasal drug delivery[J]. Adv Drug Del Rev, 1998, 29(1-2):13-38.
9. 蒋新国. 药物的鼻腔黏膜吸收[J]. 中国新药杂志, 2003, 12(11):902-905.